CA
NVIV

CoreCap Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

CoreCap Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2 Buy
+1
New +$3 ﹤0.01% 2395

Other funds holding NVIV

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CoreCap Advisors's NVIV Position: Q4 2022 in Review

CoreCap Advisors opened a new position in InVivo Therapeutics Holdings Corp (NVIV) in Q4 2022: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2395 among its holdings.

18 funds tracked by Wall St. Rank hold NVIV as of Q4 2022.

  • CoreCap Advisors held 1 share of InVivo Therapeutics Holdings Corp worth $2 as of Q4 2022.
  • InVivo Therapeutics Holdings Corp was a new CoreCap Advisors position in Q4 2022.
  • InVivo Therapeutics Holdings Corp made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #2395 holding.
  • 18 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.